Study S000600

Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02162550
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 148
Start: 2014-06
Primary completion: 2019-04
Lead sponsor: Phoenix VA Health Care System
Conditions: Type 2 Diabetes
Interventions: DRUG:Bydureon; DRUG:placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in carotid plaque volume [18 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009838	The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study. Koska J, Diabetes care	2021	Randomized trial	PMID 33495294 DOI	cites ClinicalTrials.gov:NCT02162550; registry reference DERIVED:33495294